Uric acid
Conditions
Interventions
1:Taking placebo 2 weeks
2:Taking 10 mg dapagliflozin 2 weeks
Sponsors
Weishan People's Hospital, Shandong
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Chinese males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests; 2. Aged 18 to 40 years; 3. BMI 19 to 24 kg/m2 (incl.), body weight=50kg; 4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
Exclusion criteria
Exclusion criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance; 2. Any evidence of a clinically relevant concomitant disease; 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders; 4. Surgery of the gastrointestinal tract (except appendectomy); 5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders; 6. History of relevant orthostatic hypotension, fainting spells or blackouts; 7. Chronic or relevant acute infections; 8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients); 9. within at least one month or intake of drugs with a long half-life ( less than 10 half-lives of the respective drug prior to administration or during the trial; 10. Participation in another trial with an investigational drug within two months prior to administration or during the trial; 11. Smoker; 12. Drinker; 13. Drug abuse; 14. Blood donation (more than 100 mL within four weeks prior to administration or during the trial); 15. Excessive physical activities (within one week prior to administration or during the trial); 16. Any laboratory value outside the reference range that is of clinical relevance; 17. Inability to comply with dietary regimen of trial site; 18. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Pressure;ECG;BMI; | — |
Countries
China
Contacts
Public ContactLi Xiaoe
Weishan People's Hospital, Shandong
Outcome results
None listed